Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Carisma Therapeutics, Inc. - Common Stock (NQ:CARM)

0.1926 +0.0083 (+4.50%)
Streaming Delayed Price Updated: 2:27 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 240,398
Open 0.1904
Bid (Size) 0.1903 (1)
Ask (Size) 0.1926 (9)
Prev. Close 0.1843
Today's Range 0.1809 - 0.1926
52wk Range 0.1417 - 1.900
Shares Outstanding N/A
Dividend Yield 187.44%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga

Performance

YTD
-56.2%
-56.2%
1 Month
-9.1%
-9.1%
3 Month
-58.4%
-58.4%
6 Month
-77.3%
-77.3%
1 Year
-86.3%
-86.3%

More News

Read More
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
In-Depth Examination Of 5 Analyst Recommendations For CARISMA Therapeutics
Via Benzinga
The Analyst Verdict: CARISMA Therapeutics In The Eyes Of 4 Experts
Via Benzinga
Top movers in Tuesday's session
Via Chartmill
Which stocks are experiencing notable movement on Tuesday?
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
The Latest Analyst Ratings for CARISMA Therapeutics
Via Benzinga
What 5 Analyst Ratings Have To Say About CARISMA Therapeutics
Via Benzinga
Analyst Ratings for CARISMA Therapeutics
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Wednesday?
Via Chartmill
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Why Are Carisma Therapeutics Shares Surging Friday?
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
CARM Stock Earnings: CARISMA Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
3 Top Under-$5 Stocks for Strong Gains and Positive Outlook
Via InvestorPlace
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 3, 2023
Via Benzinga

Frequently Asked Questions

Is Carisma Therapeutics, Inc. - Common Stock publicly traded?
Yes, Carisma Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Carisma Therapeutics, Inc. - Common Stock trade on?
Carisma Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Carisma Therapeutics, Inc. - Common Stock?
The ticker symbol for Carisma Therapeutics, Inc. - Common Stock is CARM on the Nasdaq Stock Market
What is the current price of Carisma Therapeutics, Inc. - Common Stock?
The current price of Carisma Therapeutics, Inc. - Common Stock is 0.1926
When was Carisma Therapeutics, Inc. - Common Stock last traded?
The last trade of Carisma Therapeutics, Inc. - Common Stock was at 05/23/25 02:27 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.